AbbVie's blood cancer drug meets late-stage trial goals
AbbVie's blood cancer drug meets late-stage trial goals Sept 3 (Reuters) - AbbVie ABBV.N said on Thursday its drug for a type of blood cancer has met the main goals of a late-stage trial.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar)
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96